CL2015000345A1 - Uso de una combinación para el melanoma que comprende la administración de cobimetinib y vemurafenib. - Google Patents

Uso de una combinación para el melanoma que comprende la administración de cobimetinib y vemurafenib.

Info

Publication number
CL2015000345A1
CL2015000345A1 CL2015000345A CL2015000345A CL2015000345A1 CL 2015000345 A1 CL2015000345 A1 CL 2015000345A1 CL 2015000345 A CL2015000345 A CL 2015000345A CL 2015000345 A CL2015000345 A CL 2015000345A CL 2015000345 A1 CL2015000345 A1 CL 2015000345A1
Authority
CL
Chile
Prior art keywords
cobimetinib
vemurafenib
melanoma
administration
combination
Prior art date
Application number
CL2015000345A
Other languages
English (en)
Inventor
Gordon Bray
Iris T Chan
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49035547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015000345(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2015000345A1 publication Critical patent/CL2015000345A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/02—Marketing; Price estimation or determination; Fundraising
    • G06Q30/0241—Advertisements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Business, Economics & Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Finance (AREA)
  • Strategic Management (AREA)
  • Development Economics (AREA)
  • Accounting & Taxation (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Business, Economics & Management (AREA)
  • Marketing (AREA)
  • Theoretical Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Economics (AREA)
  • Game Theory and Decision Science (AREA)
  • Entrepreneurship & Innovation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
CL2015000345A 2012-08-17 2015-02-13 Uso de una combinación para el melanoma que comprende la administración de cobimetinib y vemurafenib. CL2015000345A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261684673P 2012-08-17 2012-08-17
US201261705575P 2012-09-25 2012-09-25
US201261706026P 2012-09-26 2012-09-26
US201261722725P 2012-11-05 2012-11-05
US201361780708P 2013-03-13 2013-03-13

Publications (1)

Publication Number Publication Date
CL2015000345A1 true CL2015000345A1 (es) 2015-05-22

Family

ID=49035547

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015000345A CL2015000345A1 (es) 2012-08-17 2015-02-13 Uso de una combinación para el melanoma que comprende la administración de cobimetinib y vemurafenib.

Country Status (31)

Country Link
US (3) US11087354B2 (es)
EP (1) EP2884979B1 (es)
JP (2) JP6335169B2 (es)
KR (6) KR20150038068A (es)
CN (2) CN104640545A (es)
AU (1) AU2013304021B2 (es)
BR (1) BR112015003418A2 (es)
CA (2) CA2879252C (es)
CL (1) CL2015000345A1 (es)
CO (1) CO7180225A2 (es)
DK (1) DK2884979T3 (es)
EA (1) EA033573B1 (es)
ES (1) ES2743427T3 (es)
HK (1) HK1206605A1 (es)
HR (1) HRP20191533T1 (es)
HU (1) HUE044789T2 (es)
IL (1) IL237065B (es)
LT (1) LT2884979T (es)
MX (1) MX367970B (es)
MY (1) MY180613A (es)
NZ (1) NZ744862A (es)
PE (1) PE20151156A1 (es)
PH (1) PH12015500186A1 (es)
PL (1) PL2884979T3 (es)
PT (1) PT2884979T (es)
RS (1) RS59113B1 (es)
SG (3) SG10201708494QA (es)
SI (1) SI2884979T1 (es)
UA (1) UA114923C2 (es)
WO (1) WO2014027056A1 (es)
ZA (1) ZA201500348B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT4241849T (pt) 2011-10-14 2024-10-30 Hoffmann La Roche Utilizações do inibidor da dimerização de her2 pertuzumab e artigo de fabrico que inclui o mesmo
JP6335169B2 (ja) * 2012-08-17 2018-05-30 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト コビメチニブ及びメベムラフェニブを投与することを含むメラノーマの併用療法
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
WO2015095842A2 (en) 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
EP3154589A1 (en) * 2014-06-13 2017-04-19 Genentech, Inc. Methods of treating and preventing cancer drug resistance
CZ2015250A3 (cs) * 2015-04-14 2016-10-26 Zentiva, K.S. Amorfní formy vemurafenibu
CN113893253A (zh) * 2015-05-22 2022-01-07 普莱希科公司 用于治疗braf-v600相关的疾病的plx-8394或plx-7904
IL256299B2 (en) * 2015-06-30 2023-11-01 Genentech Inc Immediate-release tablets containing a drug and processes for creating the tablets
EP3370775B1 (en) 2015-11-03 2023-04-19 Genentech, Inc. Combination of bcl-2 inhibitor and mek inhibitor for the treatment of cancer
PL3377107T3 (pl) * 2015-11-19 2020-12-14 F. Hoffmann-La Roche Ag Sposoby leczenia nowotworu przy użyciu inhibitorów b-raf i inhibitorów immunologicznego punktu kontrolnego
WO2017095826A1 (en) * 2015-11-30 2017-06-08 The Regents Of The University Of California Combination therapy for treatment of melanoma
CN109689102A (zh) 2016-08-12 2019-04-26 基因泰克公司 Mek抑制剂,pd-1轴抑制剂,和vegf抑制剂的组合疗法
WO2018064299A1 (en) 2016-09-29 2018-04-05 Genentech, Inc. Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a taxane
CN110291089B (zh) 2017-01-17 2022-05-27 海帕瑞吉尼克斯股份有限公司 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂
US11077189B2 (en) 2017-03-02 2021-08-03 Genentech Inc. Adjuvant treatment of HER2-positive breast cancer
US11395823B2 (en) 2018-01-09 2022-07-26 Duke University Topical administration of MEK inhibiting agents for the treatment of skin disorders
CN109879855B (zh) * 2019-03-26 2021-01-05 中国医学科学院医药生物技术研究所 靶向肿瘤细胞表面pd-l1分子的抑制剂及其应用
WO2021229439A1 (en) * 2020-05-12 2021-11-18 Novartis Ag Therapeutic combinations comprising a craf inhibitor
EP4304592A1 (en) 2021-03-09 2024-01-17 Genentech, Inc. Belvarafenib for use in treatment of brain cancers
US20240366609A1 (en) 2021-04-06 2024-11-07 Genentech, Inc. Combination therapy with belvarafenib and cobimetinib or with belvarafenib, cobimetinib, and atezolizumab
US20230355801A1 (en) * 2022-05-09 2023-11-09 Yale University Immunotherapy of skin cancer using mpla-loaded hpg nanoparticles
WO2025008650A1 (en) * 2023-07-03 2025-01-09 Országos Onkológiai Intézet Cse inhibitor for use in the treatment of a tumor in combination with a mapk inhibitor

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002365899B2 (en) 2001-12-04 2007-09-13 Onyx Pharmaceuticals, Inc. RAF-MEK-ERK pathway inhibitors to treat cancer
TWI343377B (en) 2002-03-13 2011-06-11 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
AU2003286447A1 (en) 2003-10-16 2004-06-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatments for inhibiting development and progression of nevi and melanoma having braf mutations
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
NZ547481A (en) 2003-11-19 2009-12-24 Array Biopharma Inc Heterocyclic inhibitors of mek and methods of use thereof
PL1696920T3 (pl) 2003-12-19 2015-03-31 Plexxikon Inc Związki i sposoby opracowywania modulatorów Ret
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
US20060216288A1 (en) 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
DK2395004T3 (en) 2005-06-22 2016-03-21 Plexxikon Inc Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors
EP1913157B2 (en) 2005-06-28 2016-10-26 Genentech, Inc. Egfr and kras mutations for prediction of patient response to egfr inhibitor treatment
US9095581B2 (en) 2005-07-21 2015-08-04 Ardea Biosciences, Inc. Combinations of MEK inhibitors and Raf kinase inhibitors and uses thereof
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
WO2007013997A2 (en) 2005-07-22 2007-02-01 H. Lee Moffitt Cancer Center And Research Institute Inhibition of the raf/mek/p-erk pathway for treating cancer
EP2073810B1 (en) * 2006-09-13 2011-08-31 Takeda Pharmaceutical Company Limited Use of 2-6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile for treating diabetes, cancer, autoimmune disorders and hiv infection
CN103524392B (zh) 2005-10-07 2018-06-01 埃克塞利希斯股份有限公司 作为用于治疗增生性疾病的mek 抑制剂的吖丁啶
EP2074226A2 (en) 2006-09-19 2009-07-01 Novartis AG Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
ES2703723T3 (es) 2006-12-14 2019-03-12 Exelixis Inc Métodos para usar inhibidores de MEK
EP2412828B1 (en) 2007-03-13 2013-06-05 Amgen Inc. K-ras and B-raf mutations and anti-EGFr antibody therapy
WO2008120004A1 (en) 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
CA2924418A1 (en) 2007-07-30 2009-02-05 Jean-Michel Vernier Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same
EP2265610B1 (en) 2008-02-29 2012-12-12 Array Biopharma, Inc. Pyrazole [3, 4-b]pyridine raf inhibitors
WO2009111277A1 (en) 2008-02-29 2009-09-11 Array Biopharma Inc. Imdizo [4. 5-b] pyridine derivatives used as raf inhibitors
CN102015707A (zh) 2008-02-29 2011-04-13 阵列生物制药公司 Raf抑制剂化合物及其使用方法
EP2265574A1 (en) 2008-02-29 2010-12-29 Array Biopharma, Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
DE102008059206A1 (de) * 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
HUE027598T2 (en) 2009-04-03 2016-10-28 Hoffmann La Roche Propane-1-sulfonic acid {3- [5- (4-chlorophenyl) -1H-pyrrolo [2,3-B] pyridine-3-carbonyl] -2,4-difluorophenyl} amide compositions and their uses
MY165154A (en) 2009-08-24 2018-02-28 Genentech Inc Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
AU2010307043C1 (en) 2009-10-12 2014-03-13 Glaxosmithkline Llc Combination
NZ599939A (en) * 2009-10-12 2014-02-28 Hoffmann La Roche Combinations of a pi3k inhibitor and a mek inhibitor
WO2011104694A2 (en) 2010-02-26 2011-09-01 GAMMAGENETICS Sàrl Detection of braf v600e mutation by allele specific real time quantitative pcr (as-qpcr) using locked nucleic acids primers and beacon probes
EP2545187B1 (en) 2010-03-09 2018-09-05 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
US20120045433A1 (en) 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
WO2012027716A1 (en) 2010-08-27 2012-03-01 Collabrx, Inc. Method to treat melanoma in braf inhibitor-resistant subjects
AU2011295837B2 (en) * 2010-09-03 2015-06-18 Astrazeneca Uk Limited Drug formulations using water soluble antioxidants
EP2635286A4 (en) 2010-11-05 2014-11-12 Glaxosmithkline Ip No 2 Ltd METHOD FOR THE TREATMENT OF CANCER
WO2012068468A1 (en) 2010-11-19 2012-05-24 Glaxosmithkline Llc Method of treatment with braf inhibitor
WO2012068562A2 (en) 2010-11-19 2012-05-24 The Regents Of The University Of California Compositions and methods for detection and treatment of b-raf inhibitor-resistant melanomas
US9295669B2 (en) * 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
WO2012145503A1 (en) 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations
US20130172375A1 (en) 2011-12-13 2013-07-04 Hoffmann-La Roche Inc. Pharmaceutical composition
US9216170B2 (en) 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
JP6335169B2 (ja) * 2012-08-17 2018-05-30 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト コビメチニブ及びメベムラフェニブを投与することを含むメラノーマの併用療法
KR20150118159A (ko) 2013-02-22 2015-10-21 에프. 호프만-라 로슈 아게 암의 치료 방법 및 약물 내성의 예방 방법

Also Published As

Publication number Publication date
SI2884979T1 (sl) 2019-10-30
EA033573B1 (ru) 2019-11-06
KR20190057421A (ko) 2019-05-28
PT2884979T (pt) 2019-09-04
US20240046303A1 (en) 2024-02-08
HK1206605A1 (en) 2016-01-15
LT2884979T (lt) 2019-09-10
MY180613A (en) 2020-12-03
KR20170044759A (ko) 2017-04-25
AU2013304021B2 (en) 2016-09-15
PE20151156A1 (es) 2015-08-19
US11783366B2 (en) 2023-10-10
RS59113B1 (sr) 2019-09-30
PH12015500186A1 (en) 2015-04-06
MX367970B (es) 2019-09-11
CN110251512A (zh) 2019-09-20
ES2743427T3 (es) 2020-02-19
DK2884979T3 (da) 2019-09-02
JP6335169B2 (ja) 2018-05-30
US20140093568A1 (en) 2014-04-03
UA114923C2 (uk) 2017-08-28
JP2015531763A (ja) 2015-11-05
NZ744862A (en) 2019-06-28
CA2879252C (en) 2017-10-10
KR20150038068A (ko) 2015-04-08
US20220172244A1 (en) 2022-06-02
CA2928396A1 (en) 2014-02-20
PL2884979T3 (pl) 2019-11-29
AU2013304021A1 (en) 2015-02-12
ZA201500348B (en) 2019-07-31
BR112015003418A2 (pt) 2017-07-04
EP2884979B1 (en) 2019-06-26
IL237065B (en) 2020-07-30
HRP20191533T1 (hr) 2019-11-29
US11087354B2 (en) 2021-08-10
WO2014027056A1 (en) 2014-02-20
KR20210108502A (ko) 2021-09-02
JP2017160214A (ja) 2017-09-14
EA201590262A1 (ru) 2015-06-30
CA2879252A1 (en) 2014-02-20
KR20240146112A (ko) 2024-10-07
SG10201913359TA (en) 2020-02-27
EP2884979A1 (en) 2015-06-24
SG10201708494QA (en) 2017-11-29
CO7180225A2 (es) 2015-02-09
CN104640545A (zh) 2015-05-20
US12354130B2 (en) 2025-07-08
SG11201500582UA (en) 2015-04-29
HUE044789T2 (hu) 2019-11-28
MX2015002031A (es) 2015-06-05
KR20220165811A (ko) 2022-12-15
IL237065A0 (en) 2015-03-31

Similar Documents

Publication Publication Date Title
CL2014003136A1 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos; composicion farmaceutica que los contiene y usos.
BR112014031262A2 (pt) composições biocatalisadoras inovadoras e processos para uso.
CO6900149A2 (es) Una composición farmacéutica que comprende los fitocanabinoides canabidivarina (cbdv) y canabidiol (cbd)
BR112015000420A2 (pt) composto, composição farmacêutica, e, uso de um composto
CL2014002093A1 (es) Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
BR112016000489A2 (pt) composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
BR112015002767A2 (pt) composições, métodos, e sistemas para a síntese e uso de agentes de imagiologia
CL2015000294A1 (es) Combinaciones farmaceuticas que comprenden un inhibidor de b-raf, un inhibidor del receptor del factor de crecimiento epidermico y opcionalmente un inhibidor pi3halpha y uso en el tratamiento de una enfermedad proliferativa.
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
CL2014001047A1 (es) Compuestos heterociclicos derivados de pirazina; composicion y combinacion farmaceutica que los contienen y el uso en enfermedades respiratorias y alergicas.
BR112013030302A2 (pt) composto, composição farmacêutica, uso de um composto, combinação de um composto e dispositivo
BR112015002824A2 (pt) composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação.
BR112014029642A2 (pt) composto, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit
CL2015002803A1 (es) Una composición no nematicida y uso de los mismos
CL2014003525A1 (es) Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension.
BR112014021068A8 (pt) inibidor de uma interação entre fosfatidilserina e um receptor tim, composição farmacêutica e uso de um inibidor
GB201513741D0 (en) Positioning, quick-release bioadhesion agent and use
CL2015001458A1 (es) Composición simbiotica y el uso de la misma.
EP2976091C0 (de) Antioxidativ wirksame zusammensetzung und deren verwendung
UY34786A (es) Procedimiento para la fabricación de una forma farmacéutica que comprende nifedipino y candesartan cilexetilo
BR112013012175A2 (pt) combinação, coadministração, uso e método
BR112014025416A2 (pt) AGENTES ANTIMALÁRICOS, COMPOSIÇÃO FARMACEUTICA COMPREENDENDO-OS E USO Dos MESMOS.
BR112013023575A2 (pt) “derivado de octaidrotienoquinolina, composição farmacêutica compreendendo o derivado, e uso destes”
UY34931A (es) ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?.
IL244693B (en) History of piperazine and their use as drugs